Do Larger Models Really Win in Drug Discovery? A Benchmark Assessment of Model Scaling in AI-Driven Molecular Property and Activity Prediction
arXiv:2604.26498v3 Announce Type: replace Abstract: The rapid growth of molecular foundation models and large language models (LLMs) has encouraged a scale centred view of AI in drug discovery, in which larger pretrained models are expected to supersede compact cheminformatics models. We test this assumption across 26 ADME, toxicity and bioactivity endpoints, covering 165,541 endpoint level compound label records. The benchmark contains 78 endpoint and split entries evaluated under random, Murcko scaffold and structure separated 5-fold cross validation protocols, representing increasing chemic
The proliferation of Large Language Models (LLMs) and foundation models is driving a re-evaluation of model scaling assumptions across various scientific domains, including drug discovery.
A strategic reader should care because this research challenges a prevailing assumption in AI development, potentially redirecting investment and research efforts in AI-driven drug discovery towards more efficient or targeted approaches.
The understanding that raw model size might not be the sole or primary driver of performance in molecular property and activity prediction, suggesting a nuanced view of model scaling is necessary.
- · AI ethicists
- · Domain-specific AI developers
- · Drug discovery startups using compact models
- · Researchers focused on data quality and feature engineering
- · Developers solely focused on 'bigger is better' AI models
- · Investors funding only large-scale generic AI initiatives
- · Companies with high compute burn rates assuming linear returns from scale
- · Generalized foundation model providers entering drug discovery
Companies and research institutions will begin reassessing their strategies for AI model development in drug discovery, potentially favoring specialized or compact models over continuously larger ones.
This shift could lead to more efficient use of computational resources and potentially accelerate drug discovery by focusing on methodology and data quality rather than just scale.
A broader re-evaluation of 'scaling laws' in other scientific AI applications may follow, fostering a more nuanced understanding of AI's capabilities and limitations across various fields outside of drug discovery.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG